News
UBX
--
0.00%
--
UNITY Biotechnology to Participate in Upcoming March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior managem...
GlobeNewswire · 02/26 21:05
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
GlobeNewswire · 02/24 13:00
Unity Biotechnology cut to sell at Citi on valuation
The analysts at Citi have downgraded Unity Biotechnology ([[UBX]] +3.0%) to sell from neutral noting a near three-fold rise in company share price since August without a ‘meaningful enough change
Seekingalpha · 02/16 20:56
--Analyst Actions: Citigroup Downgrades UNITY Biotechnology to Sell From Neutral, Adjusts Price Target to $6 From $5
MT Newswires · 02/16 07:43
Unity shares surge 9% premarket on age-related eye diseases discovery
Scientists at Unity Biotechnology (UBX) and the University of Montreal say that they have discovered a novel mechanism of action for treating diseases such as diabetic retinopathy and diabetic macular
Seekingalpha · 02/08 14:18
BRIEF-Unity Biotechnology Announced New Preclinical Research That Reveals A Novel Mechanism For Treating Age-Related Eye Diseases
reuters.com · 02/08 14:03
Study published in Cell Metabolism Reveals New Therapeutic Approach Aimed at Restoring Vascular Health and Reversing Age-Related Eye Disease
Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY Biotechnology and University of Montreal provide mechanistic evidenc...
GlobeNewswire · 02/08 13:00
Unity Biotechnology (UBX) Receives a Hold from Mizuho Securities
In a report released yesterday, Salim Syed from Mizuho Securities maintained a Hold rating on Unity Biotechnology (UBX), with a price target of $4.00. The
SmarterAnalyst · 02/08 00:25
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif., Feb 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology,...
GlobeNewswire · 02/03 13:01
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from January 19, 2021 through...
GlobeNewswire · 02/03 13:00
*DJ Unity Biotechnology Names Jason Damiano as Vice Pres of Translational Biology, Nathan Guz as Vice Pres of Ops >UBX
Dow Jones · 02/01 13:01
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
SOUTH SAN FRANCISCO, Calif., Feb 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- Mike Sapieha brings world-class expertise in aging-related ophthalmologic and...
GlobeNewswire · 02/01 13:00
*DJ Unity Biotechnology Appoints Mike Sapieha as Chief Scientific Advisor >UBX
Dow Jones · 02/01 13:00
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
GlobeNewswire · 02/01 13:00
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations SOUTH SAN FRANCISCO, ...
GlobeNewswire · 02/01 13:00
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations SOUTH SAN FRANCISCO, ...
GlobeNewswire · 02/01 13:00
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
Zacks.com · 01/12 21:14
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.
Zacks · 01/12 15:44
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
Zacks · 01/12 15:44
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
Zacks · 01/12 15:44
Webull provides a variety of real-time UBX stock news. You can receive the latest news about Unity Btech through multiple platforms. This information may help you make smarter investment decisions.
About UBX
Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis, vision loss, and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules, UBX0101 and UBX1967, designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins.